Chinese medical professionals have announced a significant breakthrough in domestically developed innovative medicine. A combination of drugs created in China has demonstrated superior effectiveness compared to the current international standard treatment for a specific type of lung cancer.
The combination therapy resulted in a median progression-free survival increase of 3.9 months for cancer patients, reaching a total of 11 months. This is in comparison to those receiving the globally recognized drug pembrolizumab, which is the standard treatment. The research also showed a 30 percent reduction in the risk of disease progression and death. Pembrolizumab has been the primary treatment for patients with PD-L1-positive advanced non-small cell lung cancer, with a median progression-free survival of approximately six months.
The findings were presented at the annual meeting of the American Society of Clinical Oncology, a major clinical oncology conference. The drug combination consists of Benmelstobart injection and Anlotinib capsules, both developed by Sino Biopharmaceutical. The treatment was tested as a first-line therapy for PD-L1-positive advanced non-small cell lung cancer patients in a Phase III clinical trial involving over 500 patients.
The study was presented in the conference's highest category. The achievement highlights the therapeutic potential of innovative domestic drugs. The combination therapy has the potential to shift the landscape of international cancer treatment.
Benmelstobart is an independently developed anti-PD-L1 monoclonal antibody. Anlotinib is a multi-target anti-angiogenic tyrosine kinase inhibitor approved for the treatment of non-small cell lung cancer in China. Clinical data indicated that almost all patient subgroups benefited from the combination therapy, with improved overall response and disease control rates compared to pembrolizumab alone. The therapy may provide a superior first-line treatment option for patients with PD-L1-positive advanced non-small cell lung cancer.
Among patients with high PD-L1 expression, the median progression-free survival with pembrolizumab was 7.2 months, while the combination regimen reached 13.3 months. The researchers hope for the treatment combination to be approved soon to benefit more patients.
Lung cancer is the leading cause of cancer incidence and mortality worldwide, and in China. Non-small cell lung cancer accounts for over 80 percent of all lung cancers. At the ASCO meeting, Chinese researchers presented over 70 original research studies. Sino Biopharm had 12 clinical studies selected for oral presentations.
0 Comments